Anavex Life Sciences Corp (AVXL)

[rx7171]

Once we get the CHMP feedback we will know what they felt were the data shortcomings.
It may be such that submitting a new MAA with the fresh data now in hand would suffice.

A new Phase 3 will add three years of delay before a decision.

Maybe a better course would be to now submit a NDA with the FDA with the total data package we already have. Why not?
TGD mentioned that discussion in today’s PR.